Cargando…

The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts

Sclerostin is a bone formation inhibitor produced by osteocytes. Although sclerostin is mainly expressed in osteocytes, it was also reported in periodontal ligament (PDL) fibroblasts, which are cells that play a role in both osteogenesis and osteoclastogenesis. Here, we assess the role of sclerostin...

Descripción completa

Detalles Bibliográficos
Autores principales: Pigeaud, Karina E., Rietveld, Melanie L., Witvliet, Aster F., Hogervorst, Jolanda M. A., Zhang, Chen, Forouzanfar, Tim, Bravenboer, Nathalie, Schoenmaker, Ton, de Vries, Teun J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145870/
https://www.ncbi.nlm.nih.gov/pubmed/37108735
http://dx.doi.org/10.3390/ijms24087574
_version_ 1785034441971728384
author Pigeaud, Karina E.
Rietveld, Melanie L.
Witvliet, Aster F.
Hogervorst, Jolanda M. A.
Zhang, Chen
Forouzanfar, Tim
Bravenboer, Nathalie
Schoenmaker, Ton
de Vries, Teun J.
author_facet Pigeaud, Karina E.
Rietveld, Melanie L.
Witvliet, Aster F.
Hogervorst, Jolanda M. A.
Zhang, Chen
Forouzanfar, Tim
Bravenboer, Nathalie
Schoenmaker, Ton
de Vries, Teun J.
author_sort Pigeaud, Karina E.
collection PubMed
description Sclerostin is a bone formation inhibitor produced by osteocytes. Although sclerostin is mainly expressed in osteocytes, it was also reported in periodontal ligament (PDL) fibroblasts, which are cells that play a role in both osteogenesis and osteoclastogenesis. Here, we assess the role of sclerostin and its clinically used inhibitor, romosozumab, in both processes. For osteogenesis assays, human PDL fibroblasts were cultured under control or mineralizing conditions with increasing concentrations of sclerostin or romosozumab. For analyzing osteogenic capacity and alkaline phosphatase (ALP) activity, alizarin red staining for mineral deposition and qPCR of osteogenic markers were performed. Osteoclast formation was investigated in the presence of sclerostin or romosozumab and, in PDLs, in the presence of fibroblasts co-cultured with peripheral blood mononuclear cells (PBMCs). PDL-PBMC co-cultures stimulated with sclerostin did not affect osteoclast formation. In contrast, the addition of romosozumab slightly reduced the osteoclast formation in PDL-PBMC co-cultures at high concentrations. Neither sclerostin nor romosozumab affected the osteogenic capacity of PDL fibroblasts. qPCR analysis showed that the mineralization medium upregulated the relative expression of osteogenic markers, but this expression was barely affected when romosozumab was added to the cultures. In order to account for the limited effects of sclerostin or romosozumab, we finally compared the expression of SOST and its receptors LRP-4, -5, and -6 to the expression in osteocyte rich-bone. The expression of SOST, LRP-4, and LRP-5 was higher in osteocytes compared to in PDL cells. The limited interaction of sclerostin or romosozumab with PDL fibroblasts may relate to the primary biological function of the periodontal ligament: to primarily resist bone formation and bone degradation to the benefit of an intact ligament that is indented by every chew movement.
format Online
Article
Text
id pubmed-10145870
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101458702023-04-29 The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts Pigeaud, Karina E. Rietveld, Melanie L. Witvliet, Aster F. Hogervorst, Jolanda M. A. Zhang, Chen Forouzanfar, Tim Bravenboer, Nathalie Schoenmaker, Ton de Vries, Teun J. Int J Mol Sci Article Sclerostin is a bone formation inhibitor produced by osteocytes. Although sclerostin is mainly expressed in osteocytes, it was also reported in periodontal ligament (PDL) fibroblasts, which are cells that play a role in both osteogenesis and osteoclastogenesis. Here, we assess the role of sclerostin and its clinically used inhibitor, romosozumab, in both processes. For osteogenesis assays, human PDL fibroblasts were cultured under control or mineralizing conditions with increasing concentrations of sclerostin or romosozumab. For analyzing osteogenic capacity and alkaline phosphatase (ALP) activity, alizarin red staining for mineral deposition and qPCR of osteogenic markers were performed. Osteoclast formation was investigated in the presence of sclerostin or romosozumab and, in PDLs, in the presence of fibroblasts co-cultured with peripheral blood mononuclear cells (PBMCs). PDL-PBMC co-cultures stimulated with sclerostin did not affect osteoclast formation. In contrast, the addition of romosozumab slightly reduced the osteoclast formation in PDL-PBMC co-cultures at high concentrations. Neither sclerostin nor romosozumab affected the osteogenic capacity of PDL fibroblasts. qPCR analysis showed that the mineralization medium upregulated the relative expression of osteogenic markers, but this expression was barely affected when romosozumab was added to the cultures. In order to account for the limited effects of sclerostin or romosozumab, we finally compared the expression of SOST and its receptors LRP-4, -5, and -6 to the expression in osteocyte rich-bone. The expression of SOST, LRP-4, and LRP-5 was higher in osteocytes compared to in PDL cells. The limited interaction of sclerostin or romosozumab with PDL fibroblasts may relate to the primary biological function of the periodontal ligament: to primarily resist bone formation and bone degradation to the benefit of an intact ligament that is indented by every chew movement. MDPI 2023-04-20 /pmc/articles/PMC10145870/ /pubmed/37108735 http://dx.doi.org/10.3390/ijms24087574 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pigeaud, Karina E.
Rietveld, Melanie L.
Witvliet, Aster F.
Hogervorst, Jolanda M. A.
Zhang, Chen
Forouzanfar, Tim
Bravenboer, Nathalie
Schoenmaker, Ton
de Vries, Teun J.
The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
title The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
title_full The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
title_fullStr The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
title_full_unstemmed The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
title_short The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
title_sort effect of sclerostin and monoclonal sclerostin antibody romosozumab on osteogenesis and osteoclastogenesis mediated by periodontal ligament fibroblasts
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145870/
https://www.ncbi.nlm.nih.gov/pubmed/37108735
http://dx.doi.org/10.3390/ijms24087574
work_keys_str_mv AT pigeaudkarinae theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT rietveldmelaniel theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT witvlietasterf theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT hogervorstjolandama theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT zhangchen theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT forouzanfartim theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT bravenboernathalie theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT schoenmakerton theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT devriesteunj theeffectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT pigeaudkarinae effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT rietveldmelaniel effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT witvlietasterf effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT hogervorstjolandama effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT zhangchen effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT forouzanfartim effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT bravenboernathalie effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT schoenmakerton effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts
AT devriesteunj effectofsclerostinandmonoclonalsclerostinantibodyromosozumabonosteogenesisandosteoclastogenesismediatedbyperiodontalligamentfibroblasts